Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Developing epigenetic biomarkers for chemosensitivity in small-cell lung cancer using circulating tumour DNA

EF 2019-20

Résumé
"Lung cancer is the most common cancer killer globally. Small cell lung cancer (SCLC) is a particularly aggressive type of lung cancer that represents about 1 in 7 of all lung cancer patients. SCLC patients live on average about 8-12 months and only 7 in 100 patients survive past 5 years. Two chemotherapy drugs called cisplatin and etoposide are given to all SCLC patients. Initially, patients respond well to these chemotherapy drugs as the cancer is sensitive and shrinks after treatment. Unfortunately, for most SCLC patients, the cancer becomes resistant to the two drugs and is no longer responsive to chemotherapy. Also, some patients are resistant to chemotherapy from the get-go. Recent findings suggest that SCLC might be modifying the genetic code through indirect means i.e. epigenetics. Epigenetics is a biological process that can turn genes on and off. However, the main challenge in investigating SCLC epigenetics is the lack of tumour samples as they are difficult to obtain. This project aims to address this limitation by using blood samples collected from SCLC patients. Specifically, the aim is to use blood to understand the epigenetics of SCLC and identify molecular biomarkers that can be used to predict treatment response in patients."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
429155
Name
Ul Haq Sami
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing epigenetic biomarkers for chemosensitivity in small-cell lung cancer using circulating tumour DNA
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
5-Methylcytosine; Chemotherapy; Circulating Tumour Dna; Dna Methylation; Epigenetics; Methylated Dna Immunoprecipitation; Next-Generation Sequencing; Small-Cell Lung Cancer
Abstract
"Lung cancer is the most common cancer killer globally. Small cell lung cancer (SCLC) is a particularly aggressive type of lung cancer that represents about 1 in 7 of all lung cancer patients. SCLC patients live on average about 8-12 months and only 7 in 100 patients survive past 5 years. Two chemotherapy drugs called cisplatin and etoposide are given to all SCLC patients. Initially, patients respond well to these chemotherapy drugs as the cancer is sensitive and shrinks after treatment. Unfortunately, for most SCLC patients, the cancer becomes resistant to the two drugs and is no longer responsive to chemotherapy. Also, some patients are resistant to chemotherapy from the get-go. Recent findings suggest that SCLC might be modifying the genetic code through indirect means i.e. epigenetics. Epigenetics is a biological process that can turn genes on and off. However, the main challenge in investigating SCLC epigenetics is the lack of tumour samples as they are difficult to obtain. This project aims to address this limitation by using blood samples collected from SCLC patients. Specifically, the aim is to use blood to understand the epigenetics of SCLC and identify molecular biomarkers that can be used to predict treatment response in patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ul Haq, Sami
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~